Beth Mole, Ars Technica:
The chief executive of a small pharmaceutical company defended hiking the price of an essential antibiotic by more than 400 percent and told the Financial Times that he thinks “it is a moral requirement to make money when you can.”
Nirmal Mulye, CEO of the small Missouri-based drug company Nostrum Laboratories, raised the price of a bottle of nitrofurantoin from $474.75 to $2,392 last month. The drug is a decades-old antibiotic used to treat urinary-tract infections caused by Escherichia coli and certain other Gram-negative bacteria. The World Health Organization lists nitrofurantoin as an essential medicine.
In an interview with the FT, Mulye went on to say it was also a “moral requirement” to “sell the product for the highest price,” and he explained that he was in “this business to make money.”
In line with this perspective, Mulye took a moment to defend Martin Shkreli, who gained notoriety for buying exclusive rights to another decades-old drug and ruthlessly raised its price by more than 5,000 percent virtually overnight. (Shkreli was sentenced to seven years in prison in March on unrelated fraud charges.)